Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CERC

Cerecor (CERC) Stock Price, News & Analysis

Cerecor logo

About Cerecor Stock (NASDAQ:CERC)

Advanced Chart

Key Stats

Today's Range
$3.67
$4.00
50-Day Range
$2.06
$3.24
52-Week Range
$1.98
$4.50
Volume
32,967 shs
Average Volume
1.27 million shs
Market Capitalization
$353.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Receive CERC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerecor and its competitors with MarketBeat's FREE daily newsletter.

CERC Stock News Headlines

Aytu BioPharma Stock (NASDAQ:AYTU) Insider Trades
mTOR Inhibitors Global Market Report 2023
Why America’s building cathedrals again
While the media fixates on tariffs and market noise, something historic is unfolding behind the scenes. With backing from the White House and Silicon Valley billionaires, a vast network of AI-powered facilities is taking shape across the country. They’re being called “Cathedrals of Light” — and they hold the keys to nuclear fusion, advanced medicine, and defense breakthroughs. I’ve spent 25 years identifying seismic shifts like this — and I believe this could be the biggest one yet for early investors.
See More Headlines

CERC Stock Analysis - Frequently Asked Questions

Cerecor Inc. (NASDAQ:CERC) announced its quarterly earnings results on Sunday, August, 1st. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. The business had revenue of $3.36 million for the quarter. Cerecor had a negative net margin of 1,194.82% and a negative trailing twelve-month return on equity of 261.82%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cerecor investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), VBI Vaccines (VBIV), Pfizer (PFE) and Agile Therapeutics (AGRX).

Company Calendar

Last Earnings
8/01/2021
Today
5/14/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CERC
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-63,500,000.00
Net Margins
-1,194.82%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.70 million
Price / Cash Flow
N/A
Book Value
$0.22 per share
Price / Book
16.73

Miscellaneous

Free Float
N/A
Market Cap
$353.31 million
Optionable
Not Optionable
Beta
1.44

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:CERC) was last updated on 5/14/2025 by MarketBeat.com Staff
From Our Partners